Pyxis Oncology (PYXS) Expected to Release Earnings on Monday

Pyxis Oncology (NASDAQ:PYXS) is projected to announce its Q3 2026 results before the market opens on Monday, November 2nd. Analysts expect Pyxis Oncology to announce earnings of ($0.27) per share for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 6, 2026 at 9:30 AM ET.

Pyxis Oncology (NASDAQ:PYXS) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). On average, analysts expect Pyxis Oncology to post ($1.21) EPS for the current fiscal year and ($1.10) EPS for the next fiscal year.

Pyxis Oncology Stock Performance

Shares of Pyxis Oncology stock opened at $1.81 on Friday. Pyxis Oncology has a 1 year low of $1.03 and a 1 year high of $5.55. The company has a market capitalization of $150.97 million, a P/E ratio of -1.28 and a beta of 1.37. The company’s fifty day moving average is $2.66 and its two-hundred day moving average is $2.16.

Analyst Ratings Changes

A number of equities research analysts have recently commented on PYXS shares. Wedbush upped their target price on shares of Pyxis Oncology from $6.00 to $8.00 and gave the company an “outperform” rating in a report on Thursday, September 10th. Weiss Ratings reissued a “sell (e+)” rating on shares of Pyxis Oncology in a report on Friday, September 25th. Wells Fargo & Company boosted their price target on Pyxis Oncology from $12.00 to $19.00 and gave the company an “overweight” rating in a research report on Wednesday, September 9th. Finally, HC Wainwright boosted their price target on Pyxis Oncology from $7.00 to $8.00 and gave the company a “buy” rating in a research report on Thursday, September 10th. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $8.75.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc is a clinical-stage biotechnology company focused on developing antibody-based therapies for the treatment of cancer. The company aims to address limitations of existing cancer treatments by designing therapeutics intended to selectively target tumors and activate the immune system while minimizing effects on healthy tissue.

Pyxis Oncology’s pipeline includes antibody-drug conjugates and immunotherapies designed to act on targets in the tumor microenvironment. Its lead programs have included PYX-201, an antibody-drug conjugate intended to deliver a cytotoxic payload to tumors expressing the fibronectin extra domain-B target, and other investigational antibody-based programs directed at immune-suppressive pathways.